Compugen Ltd. (CGEN)
CGEN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1119774/000117891326000663/0001178913-26-000663-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CGEN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Israel |
| IPO year | 2000 |
| SEC CIK | 0001119774 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $72.8M |
| Net income | $35.3M |
| Operating income | $31.3M |
| Net margin | 48.6% |
| Operating margin | 43.1% |
| Revenue growth | +161.1% |
| Cash | $90.6M |
| Total assets | $156.6M |
| P/E (computed) | 5.5× |
| P/S (computed) | 2.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-02 |
| Cash and burn | $90.6M cash; operating cash flow $7.9M a quarter. | Report 2025-12-31 |
| Shares outstanding | 94,553,191 (2025-12-31); 89,541,246 a year earlier; 86,624,643 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-05-18 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kost Forer Gabbay & Kasierer, Tel Aviv, Israel | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $118K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $72.8M | $35.3M | $31.6M | $90.6M | No debt tags | $72.8M | 20-F 2026-03-02 |
| FY 2024 2024-12-31 | $27.9M | -$14.2M | $49.6M | $18.2M | No debt tags | $27.9M | 20-F 2026-03-02 |
| FY 2023 2023-12-31 | $33.5M | -$18.8M | -$35.9M | $13.9M | No debt tags | $33.5M | 20-F 2026-03-02 |
| FY 2022 2022-12-31 | $7.5M | -$33.7M | -$34.1M | $11.1M | No debt tags | $7.5M | 20-F 2025-03-04 |
| FY 2021 2021-12-31 | $6.0M | -$34.2M | -$22.7M | $7.8M | No debt tags | $6.0M | 20-F 2024-03-05 |
| FY 2020 2020-12-31 | $2.0M | -$29.7M | -$28.3M | $7.1M | No debt tags | $2.0M | 20-F/A 2023-08-23 |
| FY 2019 2019-12-31 | Not filed | -$27.3M | -$27.9M | $9.2M | No debt tags | Needs four quarters | 20-F 2022-02-28 |
| FY 2018 2018-12-31 | $17.8M | -$22.6M | -$13.3M | $5.9M | No debt tags | $17.8M | 20-F 2021-02-25 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | F-3 | 2026-05-18 |
| Latest annual report | 20-F | 2026-03-02 |
| Latest quarterly / interim | 6-K | 2026-11-09 |
Source: SEC EDGAR submissions feed, 608 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +7.1% |
| 1 month | +6.1% |
| 3 months | -12.9% |
| Year to date | +37.3% |
| 1 year | +27.3% |
| From 52-week high | -32.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ARTV | Artiva Biotherapeutics Inc. | $3.96 | -1.25% | $195.8M |
| LCTX | Lineage Cell Therapeutics Inc. | $0.7951 | -13.07% | $201.1M |
| PALI | Palisade Bio Inc. | $1.03 | -8.04% | $184.7M |
| IKT | Inhibikase Therapeutics Inc. | $1.45 | -4.61% | $203.4M |
| IVVD | Invivyd Inc. | $0.5377 | -7.63% | $158.5M |
| IPHA | Innate Pharma S.A. ADS | $1.41 | -1.06% | $156.9M |
| CABA | Cabaletta Bio Inc. | $1.11 | -13.28% | $239.4M |
| STRO | Sutro Biopharma Inc. | $9.32 | -5.09% | $154.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier